NEWS UK pledges £85 million to tackle AMR


A package of up to £85 million to support the international community in tackling the growing threat of antimicrobial resistance has been announced by the UK Government. World leaders and experts, including the Chancellor of the Exchequer and the World Bank attended a global event during May, hosted by the Royal Society to agree priority actions to tackle antimicrobial resistance (AMR) and hear accounts from AMR survivors. The UK Government has announced the following initiatives: n Up to £50 million to partner with countries in Africa for improving access to essential antimicrobial drugs, building on ongoing work by the UK Global AMR


Partnership aims to develop new TBI diagnostics


Danaher has launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild traumatic brain injury (TBI). As part of the Danaher Beacons programme, researchers at Johns Hopkins University will leverage technology from Danaher subsidiary Beckman Coulter Diagnostics to establish correlations between a new biomarker panel and clinical outcomes. Nearly 56 million mild TBI patients worldwide could benefit from a more precise approach to diagnosis. While computed tomography (CT) is used to visualise tissue damage and diagnose moderate to severe TBI, mild TBI correlates poorly with abnormalities on head CTs. Doctors therefore need a better way to decide which patients should undergo a CT scan and identify patients who have a higher risk of developing incapacitating symptoms. The Beacon builds on recent


neurological biomarker research and next-generation immunoassay detection technology developed by Beckman Coulter Diagnostics. If effective, the approach could potentially be adapted for the diagnosis of other types of brain injury or neurodegenerative diseases. The research will be led by Jessica Gill PhD MSN BSN RN, Professor at the Johns Hopkins School of Nursing and Richard Rothman MD PhD, Professor of Emergency Medicine at Johns Hopkins Medicine.


WWW.PATHOLOGYINPRACTICE.COM JUNE 2024 Innovation Fund.


n Up to £25 million which will include partnering with countries and territories in the Caribbean to strengthen surveillance systems for AMR to enable accurate monitoring of threats.


n Up to £10 million over the next five years to help establish a Global Independent Scientific Panel for AMR, modelled on the success of other international panels. This is in partnership with the Kingdom of Saudi Arabia, which has agreed to match this funding.


In addition to these new programmes, £1.8 million has already been to create a dedicated MHRA team to support creating novel antimicrobials and diagnostics.


These new projects build on ongoing


international and domestic work to prevent the spread of antimicrobial resistance. This includes the recently announced National Action Plan and a partnership with countries across Asia and Africa to tackle AMR and reduce the threat posed to the UK, through the Fleming Fund backed by £210 million. The event – The World Together Solving the Antibiotic Emergency – was organised by the government in partnership with The Royal Society. It celebrated the successes of global action to tackle AMR and looked ahead to commitments for what more the world can do collaboratively in the fight against AMR, ahead of the important milestone of the United Nations High-Level Meeting on AMR in September.


TIME IS OF THE ESSENCE


WHEN FIGHTING ANTIMICROBIAL RESISTANCE


MAESTRIA™ ETEST® Optimised


Antimicrobial Stewardship


VITEK® 2


BACT/ALERT® VIRTUO®


BIOFIRE®


VITEK®MS PRIME


CLARION™ Lab Analytics


VITEK® REVEAL


bioMérieux puts diagnostics at the heart of Antimicrobial Stewardship with the most comprehensive diagnostic solution on the market to drive informed therapy decisions.


Our actionable diagnostics and innovative integrated software solutions paired with unrivalled support and educational resources, enables laboratories to provide fast, optimised and data-driven results to improve patient outcomes and facilitate antimicrobial stewardship.


bioMérieux is your trusted partner for diagnostic tools to support responsible use of antimicrobials throughout the patient therapy pathway.


11


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56